在瘤发生,瘤进展和治疗耐药性的表观遗传动力学和分子机制
Mohammed Kaleem1, Lubna Azmi2, Naiyer Shahzad3
1Department of Pharmacology, Dadasaheb Balpande College of Pharmacy, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, Maharashtra, India.
Naunyn-Schmiedeberg's archives of pharmacology
|May 13, 2025
概括
癌症的进展涉及复杂的遗传和表观遗传变化. 了解这些分子机制和瘤微环境是开发有针对性的疗法以获得更好的治疗结果的关键.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 癌症的进展是由复杂的遗传,表观遗传和分子相互作用驱动的.
- 关键的瘤基因 (RAS,MYC) 和瘤抑制基因 (TP53,PTEN) 经常发生改变.
- 基因组不稳定性和表观遗传修饰显著影响瘤发育和治疗耐药性.
研究的目的:
- 审查控制癌症进展的分子途径,包括遗传和表观遗传变化.
- 突出瘤微环境在调节癌症中的作用.
- 强调需要创新的,有针对性的治疗策略.
主要方法:
- 关于瘤发生的分子机制的文献综述.
- 对遗传变化的分析 (突变,放大,转移).
- 对表观遗传修饰的检查 (DNA甲基化,基因素乙化,非编码RNAs).
- 讨论翻译后的修改 (SUMOylation,无处不在).
- 包括CRISPR-Cas9和单细胞RNA测序等先进技术.
- 探索瘤微环境因素 (瘤重塑,免疫逃避,缺氧).
主要成果:
- 瘤基因和瘤抑制剂的遗传变化是癌症发病的核心原因.
- 基因组不稳定性有助于瘤异质性和进化.
- 表观遗传变化和翻译后修饰影响基因表达,细胞存活和治疗反应.
- 瘤微环境在癌症进展和药物耐药性方面发挥着关键作用.
结论:
- 对癌症的分子,遗传和表观遗传复杂性的全面了解是必不可少的.
- 针对性的治疗方法对于克服癌症的适应性至关重要.
- 整合多样化的生物见解可以导致更有效的癌症治疗.
相关概念视频
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Tumor Progression
6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
The Tumor Microenvironment
6.4K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.4K


